On November 29, 2019, approved by the State Council, the Leading Group for Deepening the Reform of the Medical and Health System Issued the Notice on Several Policies and Measures to Further Deepen the Reform of the Medical and Health System with Centralized Procurement & Use of Drugs as a Breakthrough in order to implement the decisions and plans of the CPC central Committee and the State Council on deepening the reform of the medical and health care systems and promote the interlocked reform of health care, health insurance, and pharmaceuticals. 

The Notice pointed out that it is necessary to promote the interlocked reform of health care, health insurance, and pharmaceuticals, magnify the effects of reform, and better address the problems complicating medical services to the people, the following policies and measures shall be implemented, covering 15 aspects: 

1. Deepening the reform of state-led centralized procurement and use of drugs 

2. Establishing a national pharmaceutical public procurement market and a multiparty interlocked procurement structure

3. Improving the quality of drugs

4. Ensuring stable supply of drugs

5. Hoisting the efficiency of drug payment

6. Promoting the construction of a unified and open pharmaceutical production & distribution market nationwide

7. Promoting interlocked reforms such as the dynamic adjustment of medical service prices

8. Vigorously promoting the reform of the salary system for health staff

9. Strenthening the standarized management of medical institutions' prescription practices

10. Promoting the implementation of medical insurance payment standards for drugs

11. Deepening the reform of medical insurance payment methods

12. Ameliorating the supervision mechanism of medical insurance funds

13. Promoting fine-grained supervision of medical services

14. Improving the national drug price monitoring system

15. Accelerating the application of IT in healthcare

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.